{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:26:01Z","timestamp":1790821561106,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40261-024-01397-5","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:22:32Z","timestamp":1730107352000},"page":"829-838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Clara","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alonso-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ag\u00fcera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Montero-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Gonz\u00e1lez-Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Reyes-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Caminero-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Riancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"P\u00e9rez-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Ares-Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Arzalluz-Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Casado-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Jos\u00e9","family":"Castellano-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Borrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A. Rodr\u00edguez","family":"de Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Tom\u00e1s","family":"Cano-Orgaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"S\u00e1nchez-Menoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuencisla","family":"Guti\u00e9rrez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hern\u00e1ndez-Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"2","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/2319-4170.130317","volume":"37","author":"FC Wei","year":"2014","unstructured":"Wei FC. Multiple sclerosis. Biomed J. 2014;37(2):33.","journal-title":"Biomed J"},{"key":"1397_CR2","unstructured":"Atlas of MS. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms. Accessed 22 Jan 2024."},{"issue":"1","key":"1397_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.33588\/rn.6901.2018477","volume":"69","author":"N Perez-Carmona","year":"2019","unstructured":"Perez-Carmona N, Fernandez-Jover E, Sempere AP. Epidemiology of multiple sclerosis in Spain. Rev Neurol. 2019;69(1):32\u20138.","journal-title":"Rev Neurol"},{"key":"1397_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/817238","volume":"2015","author":"KA McKay","year":"2015","unstructured":"McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;2015: 817238.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1397_CR5","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"5","key":"1397_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"FF Konen","year":"2023","unstructured":"Konen FF, M\u00f6hn N, Witte T, Schefzyk M, Wiestler M, Lovric S, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22(5): 103312.","journal-title":"Autoimmun Rev"},{"key":"1397_CR7","unstructured":"Biogen: Vumerity Prescribing Information. 2020. https:\/\/www.vumerityhcp.com\/content\/dam\/commercial\/vumerity\/hcp\/en_us\/pdf\/vumerity-prescribing-information.pdf. Accessed 22 Jan 2024."},{"key":"1397_CR8","unstructured":"B.V. BN: VUMERITY\u00ae Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vumerity-epar-product-information_en.pdf. Accessed 22 Jan 2024."},{"issue":"2","key":"1397_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/neurolint13020022","volume":"13","author":"AA Berger","year":"2021","unstructured":"Berger AA, Sottosanti ER, Winnick A, Izygon J, Berardino K, Cornett EM, et al. Monomethyl fumarate (MMF, Bafiertam) for the treatment of relapsing forms of multiple sclerosis (MS). Neurol Int. 2021;13(2):207\u201323.","journal-title":"Neurol Int"},{"key":"1397_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104500","volume":"70","author":"FS Rousseau","year":"2023","unstructured":"Rousseau FS, Wang L, Sprague TN, Lategan TW, Berkovich RR. Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam\u00ae (monomethyl fumarate) versus Vumerity\u00ae (diroximel fumarate). Mult Scler Relat Disord. 2023;70: 104500.","journal-title":"Mult Scler Relat Disord."},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"175628642199399","DOI":"10.1177\/1756286421993999","volume":"14","author":"A Wundes","year":"2021","unstructured":"Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"1397_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17(5):236\u201343.","journal-title":"Int J MS Care."},{"issue":"3","key":"1397_CR13","volume":"3","author":"B Vollmer","year":"2017","unstructured":"Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. Mult Scler J Exp Transl Clin. 2017;3(3): 2055217317725102.","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"6","key":"1397_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7224\/1537-2073.2017-109","volume":"20","author":"LD Lynd","year":"2018","unstructured":"Lynd LD, Henrich NJ, Hategeka C, Marra CA, Mittmann N, Evans C, et al. Perspectives of patients with multiple sclerosis on drug treatment: a qualitative study. Int J MS Care. 2018;20(6):269\u201377.","journal-title":"Int J MS Care."},{"issue":"2","key":"1397_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396.","journal-title":"CNS Drugs"},{"issue":"13","key":"1397_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729\u201339.","journal-title":"Mult Scler"},{"issue":"4","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","volume":"39","author":"S Wray","year":"2022","unstructured":"Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810\u201331.","journal-title":"Adv Ther"},{"issue":"14","key":"1397_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/13524585231205708","volume":"29","author":"BA Singer","year":"2023","unstructured":"Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2023;29(14):1795\u2013807.","journal-title":"Mult Scler"},{"issue":"11","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","volume":"36","author":"MJ Palte","year":"2019","unstructured":"Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36(11):3154\u201365.","journal-title":"Adv Ther"},{"issue":"5","key":"1397_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40263-023-01002-x","volume":"37","author":"T Jiang","year":"2023","unstructured":"Jiang T, Ziemssen T, Wray S, Shen C, S\u00f6derb\u00e4rg K, Lewin JB, et al. Matching-adjusted indirect comparisons of diroximel fumarate, ponesimod, and teriflunomide for relapsing multiple sclerosis. CNS Drugs. 2023;37(5):441\u201352.","journal-title":"CNS Drugs"},{"issue":"1","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40120-022-00413-0","volume":"12","author":"B Lager","year":"2023","unstructured":"Lager B, Liseno J, Bo\u017ein I, England SM, Shankar SL, Mendoza JP, et al. Real-world analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2023;12(1):145\u201359.","journal-title":"Neurol Ther."},{"issue":"1","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-021-00242-7","volume":"10","author":"J Liseno","year":"2021","unstructured":"Liseno J, Lager B, Miller C, Shankar SL, Mendoza JP, Lewin JB. Multiple sclerosis patients treated with diroximel fumarate in the real-world setting have high rates of persistence and adherence. Neurol Ther. 2021;10(1):349\u201360.","journal-title":"Neurol Ther."},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.2147\/DDDT.S236926","volume":"16","author":"L Hauer","year":"2022","unstructured":"Hauer L, Sellner J. Diroximel fumarate as a novel oral immunomodulating therapy for relapsing forms of multiple sclerosis: a review on the emerging data. Drug Des Devel Ther. 2022;16:3915\u201327.","journal-title":"Drug Des Devel Ther."},{"key":"1397_CR24","unstructured":"Neurolog\u00eda SEd. Manual de pr\u00e1ctica cl\u00ednica en esclerosis m\u00faltiple, NMO y MOGAD. Recomendaciones diagn\u00f3stico-terape\u00faticas de la SEN 2023. 2023. https:\/\/www.sen.es\/pdf\/2023\/GuiaEsclerosis_2023web.pdf. Accessed 22 Jan 2024."},{"issue":"4","key":"1397_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","volume":"11","author":"L Araujo","year":"2022","unstructured":"Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J. Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735\u201348.","journal-title":"Neurol Ther."},{"issue":"9","key":"1397_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/1352458520964778","volume":"27","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C. Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler. 2021;27(9):1391\u2013402.","journal-title":"Mult Scler"},{"issue":"3","key":"1397_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14737175.2021.1886082","volume":"21","author":"D Jakimovski","year":"2021","unstructured":"Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother. 2021;21(3):353\u201364.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"1397_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","volume":"8","author":"J Min","year":"2019","unstructured":"Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, et al. Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. Neurol Ther. 2019;8(1):109\u201319.","journal-title":"Neurol Ther."},{"issue":"1","key":"1397_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","volume":"18","author":"EJ Fox","year":"2016","unstructured":"Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9\u201318.","journal-title":"Int J MS Care."},{"issue":"16_supplement","key":"1397_CR30","doi-asserted-by":"publisher","first-page":"P3.109","DOI":"10.1212\/WNL.86.16_supplement.P3.109","volume":"86","author":"D Ontaneda","year":"2016","unstructured":"Ontaneda D, Vollmer B, Sillau S, Cohn S, Nair K, Bermel R, et al. Comparative efficacy and discontinuation of fingolimod and dimethyl fumarate in two large academic medical centers (P3. 109). Neurology. 2016;86(16_supplement):P3.109.","journal-title":"Neurology"},{"issue":"Suppl 16","key":"1397_CR31","doi-asserted-by":"publisher","first-page":"P6168","DOI":"10.1212\/WNL.86.16_supplement.P6.168","volume":"86","author":"N Vu","year":"2016","unstructured":"Vu N, Bradshaw M, Moses H, Sriram S, Pawate S. Efficacy and tolerability of fingolimod, dimethyl fumarate, and teriflunomide in patients with multiple sclerosis: real world experience from a single center. Neurology. 2016;86(Suppl 16):P6168.","journal-title":"Neurology"},{"key":"1397_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104081","volume":"67","author":"J Ravn","year":"2022","unstructured":"Ravn J, Jensen HB, Kant M, Andersen PB, G\u00f3ra MK, Sejbaek T. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. Mult Scler Relat Disord. 2022;67: 104081.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1397_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458520949158","volume":"28","author":"AL Jordan","year":"2022","unstructured":"Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 2022;28(1):7\u201315.","journal-title":"Mult Scler"},{"issue":"3","key":"1397_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/nmt-2020-0049","volume":"11","author":"J Meca-Lallana","year":"2021","unstructured":"Meca-Lallana J, Garc\u00eda-Merino JA, Mart\u00ednez-Y\u00e9lamos S, Vidal-Jordana A, Costa L, Eichau S, et al. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021;11(3):251\u201361.","journal-title":"Neurodegener Dis Manag."},{"issue":"1","key":"1397_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/pharmaceutics16010120","volume":"16","author":"CY Lee","year":"2024","unstructured":"Lee CY, Chan KH. Personalized use of disease-modifying therapies in multiple sclerosis. Pharmaceutics. 2024;16(1):120.","journal-title":"Pharmaceutics"},{"key":"1397_CR36","unstructured":"West SL, Gartlehner G, Mansfield AJ, Poole C, Tant E, Lenfestey N, et al. Comparative effectiveness review methods: clinical heterogeneity. 2010. Report No.: 10-EHC070-EF."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01397-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01397-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01397-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T10:24:20Z","timestamp":1732962260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01397-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01397-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"17 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain) with funding from Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.A. has received lecture honoraria, consultancy fees, and travel expenses from Biogen, Bristol Mayers Squibb, Merck, Novartis, Sanofi-Genzyme and Roche. A.A.T. has received fees as a speaker, consultant or travel support from Biogen, Almirall, Merck, Roche, Sanofi, Sandoz and Janssen. E.A. has no disclosures for financial affiliation, financial support nor grants moneys and has disclosure for speaker honorarium from Novartis, Merck and Biogen. JM.G.D. has received compensation as a consultant, researcher, or speaker from Biogen, Sanofi, Roche, Zenas Biopharma, Almirall, Novartis, Merck, Bristol-Myers-Squidd, and Johnson & Johnson. PM-E has received speaker and consultation fees from Allergan, Almirall, Biogen Idec, Merck, Merz, Novartis and Sanofi-Genzyme. V.G.Q has no conflict of interest related to this work. L.C.F. has received lecture honoraria, consultancy fees, clinical research funding, and travel expenses from Almirall, Amgen, AstraZeneca, Biogen, Bristol Mayers Squibb, Janssen, Merck, Neuraxpharma, Novartis, Sanofi-Genzyme, Roche. C.O.G. has received speaker and consultation fees from Alexion, Biogen Idec, BMS, Horizon, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. V.R.G. has received fees as a speaker, consultant or travel support from Almirall, Merck, Alexion, Roche and Sanofi. AB.C.R. has received honoraria as speaker\/meeting moderator\/courses\/symposium organized by Almirall Prodesfarma S.A, Biogen Idec Inc, Bristol-Myers-Squibb, Janssen Pharmaceutical; Merck-Serono, Mylan, Novartis Pharmaceutical, Roche, Sanofi-Genzyme, Teva Pharmaceuticals; and for congress assistance from Biogen Idec Inc, Bial, Merck-Serono, Novartis Pharmaceutical, Roche, Sanofi-Genzyme, Teva Pharmaceuticals. J.R. has received speaking\/consulting fees and\/or travel funding from Merck, Sanofi-Genzyme, Roche, Biogen, Novartis, BMS, Jannsen and Teva. O.S. has received fees from Almirall, Biogen, Novartis, Merck, Sanofi, Alter, Bial, Teva, Neuraxfarma, Esteve, Pfizer, Roche and UCB. L.F. has no conflict of interest related to this work. F.P.P has no conflict of interest related to this work. A.A.R. has received fees as a speaker and advisor, and funding for attendance at congresses and other medical meetings, from Bayer, Biogen, Bristol, Janssen, Merck, Novartis, Roche, Sanofi and Teva. J.A.L. received consultant fees from Merck. F.I. has received speaker honoraria and travel reimbursement from Biogen, Merck, Novartis, Roche Spain, and Genzyme-Sanofi. V.C.R has no conflict of interest related to this work. AJ.C.V. has no conflict of interest related to this work. L.B. has no conflict of interest related to this work. V.G. has received speaker fees from Merck, Roche, Biogen, Novartis and Sanofi. L.A.R.A. declares to have received travel aid and financial compensation for talks from BMS and Novartis. R.G.R received payments from Biogen for participating in training conferences. AT.C.O. has received payments from Biogen for participating in training conferences for other professionals. JL.S.M. accepted travel compensation from Novartis, Merck and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in clinical trials by Biogen, Sanofi, Merck and Roche. D.P.R. has received honoraria as a speaker, funding to attend courses and conferences, and consultancies and research grants from Merck, Biogen, Novartis, Sanofi, Teva, Roche and Almirall. F.G.M has received speaker honoraria and travel reimbursement from Biogen, Merck, Novartis, Roche Spain, and Genzyme-Sanofi. L.H.E. has received speaker and consultation fees from Biogen, Merck, Novartis, Roche and Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research protocol received approval from the independent ethics committee at the Hospital Universitario de La Princesa (10 November 2022, acta CEIM 5723).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This investigation adhered to the principles of the Helsinki Declaration and complied with the EU General Data Protection Regulation (GDPR). All personal identifiers were excluded from the findings.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"CAH and VML made substantial contributions to the conception and design of the work, interpretation of data and drafting the manuscript. All authors contributed to the acquisition of data and revised the manuscript and approved the version to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}